Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: Cancer Lett. 2009 May 15;284(2):175–181. doi: 10.1016/j.canlet.2009.04.022

Figure 1.

Figure 1

Effects of 4HPR on growth of non-malignant PBSCs, MSCs, HUVEC, osteoblasts and osteoclasts, and on MM cell growth in the absence and presence of serum and osteoclasts. A) MM cell lines (ARP-1, BN, CAG and JB), MSCs and PBMCs were treated with indicated concentrations of 4HPR in RPMI 1640 medium supplement with 10% serum for 48 hrs before subjected to MTT assay. Statistical analysis shown the table (upper panel) compared treatment groups versus control. B) Mature osteoclasts, osteoblasts and HUVEC were similarly treated with 4HPR in culture media for 48 hrs and assayed by MTT. C) MM Cells were co-cultured with osteoclasts in the presence or absence of 4HPR for 72 hrs in RPMI 1640 medium supplemented with 10% serum before subjected to MTT assay. D) MM cell lines (ARP-1 and CAG) were cultured in COMPLETE™ medium supplemented with different concentrations of serum and treated with indicated concentrations of 4HPR for 72 hrs. Statistical analysis shown compared Different serum concentrations versus control. Note that 4HPR was not toxic to PBMCs, MSCs or osteoblasts but inhibited growth of MM cell lines and mature osteoclasts in a dose-dependent manner. Serum and osteoclasts partially protected MM cells from 4HPR-induced growth inhibition. (# p<0.05; ## p<0.01; * p<0.001; ** p<0.0001)